ZA200403409B - Methods for treating depression and other CNS disorders using enantiomerically enriched desmethyl- and didesmethyl-metabolites of citalopram. - Google Patents

Methods for treating depression and other CNS disorders using enantiomerically enriched desmethyl- and didesmethyl-metabolites of citalopram.

Info

Publication number
ZA200403409B
ZA200403409B ZA200403409A ZA200403409A ZA200403409B ZA 200403409 B ZA200403409 B ZA 200403409B ZA 200403409 A ZA200403409 A ZA 200403409A ZA 200403409 A ZA200403409 A ZA 200403409A ZA 200403409 B ZA200403409 B ZA 200403409B
Authority
ZA
South Africa
Prior art keywords
didesmethyl
desmethyl
citalopram
metabolites
methods
Prior art date
Application number
ZA200403409A
Other languages
English (en)
Inventor
Larry R Bush
Chirs H Senanayake
Mark G Currie
Kevin Q Fang
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Publication of ZA200403409B publication Critical patent/ZA200403409B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
    • C07D317/20—Free hydroxyl or mercaptan

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200403409A 2001-11-08 2004-05-05 Methods for treating depression and other CNS disorders using enantiomerically enriched desmethyl- and didesmethyl-metabolites of citalopram. ZA200403409B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33760801P 2001-11-08 2001-11-08

Publications (1)

Publication Number Publication Date
ZA200403409B true ZA200403409B (en) 2005-10-26

Family

ID=23321236

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200403409A ZA200403409B (en) 2001-11-08 2004-05-05 Methods for treating depression and other CNS disorders using enantiomerically enriched desmethyl- and didesmethyl-metabolites of citalopram.

Country Status (17)

Country Link
US (1) US20040266864A1 (ko)
EP (1) EP1446396A1 (ko)
JP (1) JP2005510518A (ko)
KR (1) KR20050043776A (ko)
CN (1) CN1705654A (ko)
AU (1) AU2002356903A2 (ko)
BR (1) BR0213949A (ko)
CA (1) CA2465186A1 (ko)
HU (1) HUP0401934A3 (ko)
IL (1) IL161617A0 (ko)
MX (1) MXPA04004368A (ko)
NO (1) NO20042013L (ko)
NZ (1) NZ532478A (ko)
PL (1) PL368452A1 (ko)
RU (1) RU2004117211A (ko)
WO (1) WO2003040121A1 (ko)
ZA (1) ZA200403409B (ko)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007002597A2 (en) 2005-06-27 2007-01-04 Biovail Laboratories International S.R.L. Modified-release formulations of a bupropion salt
WO2007027476A2 (en) * 2005-08-26 2007-03-08 Xenoport, Inc. Treating premature ejaculation using gabapentin and pregabalin prodrugs
AU2007332904A1 (en) * 2006-12-08 2008-06-19 Xenoport, Inc. Use of prodrugs of GABA analogs for treating diseases
KR101103118B1 (ko) * 2007-11-02 2012-01-04 동아제약주식회사 신규한 1,3-디히드로-5-이소벤조퓨란카르보니트릴 유도체 화합물 및 이를 함유하는 조루증 치료용 약학조성물
US9056850B2 (en) * 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
WO2010075863A1 (en) * 2008-12-29 2010-07-08 University Of Tartu (Tartu Ülikool) Arginase inhibitors for the treatment of depression
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
CN102648196B (zh) 2009-10-14 2016-04-27 詹森药业有限公司 可用作sglt2的抑制剂的化合物的制备方法
EP2377522B1 (en) * 2010-04-15 2013-01-16 Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi Orally disintegrating tablet formulations of mirtazapine and process for preparing the same
CN108354930A (zh) 2010-05-11 2018-08-03 詹森药业有限公司 包含1-(β-D-吡喃葡萄糖基)-2-噻吩基-甲基苯衍生物的药物制剂
US10544135B2 (en) 2011-04-13 2020-01-28 Janssen Pharmaceutica Nv Process for the preparation of compounds useful as inhibitors of SGLT2
KR101427221B1 (ko) * 2012-08-29 2014-08-13 주식회사 에스텍파마 플루복사민 자유 염기의 정제방법 및 이를 이용한 고순도 플루복사민 말레이트의 제조방법
EP3256466B9 (en) * 2015-02-11 2022-07-27 Sunovion Pharmaceuticals Inc. 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2805812A1 (fr) * 2000-02-24 2001-09-07 Lundbeck & Co As H Procede de preparation du citalopram
IES20010157A2 (en) * 2000-03-03 2002-03-06 Lundbeck & Co As H Method for the preparation of citalopram
CN1427835A (zh) * 2000-03-13 2003-07-02 H·隆德贝克有限公司 5－取代的1－(4－氟苯基)－1,3－二氢异苯并呋喃的分步烷基化
EP1181713B1 (en) * 2000-12-22 2004-09-29 H. Lundbeck A/S Method for the preparation of pure citalopram

Also Published As

Publication number Publication date
NO20042013L (no) 2004-05-14
CN1705654A (zh) 2005-12-07
IL161617A0 (en) 2004-09-27
KR20050043776A (ko) 2005-05-11
US20040266864A1 (en) 2004-12-30
NZ532478A (en) 2007-02-23
BR0213949A (pt) 2004-08-31
PL368452A1 (en) 2005-03-21
JP2005510518A (ja) 2005-04-21
WO2003040121A1 (en) 2003-05-15
MXPA04004368A (es) 2004-08-11
EP1446396A1 (en) 2004-08-18
AU2002356903A2 (en) 2003-05-19
CA2465186A1 (en) 2003-05-15
HUP0401934A2 (hu) 2005-01-28
RU2004117211A (ru) 2005-03-27
HUP0401934A3 (en) 2007-05-29

Similar Documents

Publication Publication Date Title
MXPA03007960A (es) Compuestos y metodos para el tratamiento de desordenes urogenitales.
GB0007193D0 (en) Treatment of movrmrnt disorders
PL373626A1 (en) Treatment for central nervous system disorders
EP1471909A4 (en) PHARMACEUTICAL COMPOSITION AND METHOD FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM
EP1443929A4 (en) TREATMENT OF CNS DISTURBANCES WITH CNS TARGET MODULATORS
HUP0501017A2 (en) Methods and compositions for treatment of central nervous system disorders
ZA200403409B (en) Methods for treating depression and other CNS disorders using enantiomerically enriched desmethyl- and didesmethyl-metabolites of citalopram.
IL155589A0 (en) Novel amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders
IL160561A0 (en) Method and composition for treating immune complex associated disorders
HK1041880A1 (en) Compounds and methods for treatment of asthma, allergy and inflammatory disorders.
HUP0600156A2 (en) Benzofuran and benzothiophene deruvatives useful in the treatment of hyper-proliferative disorders
PL369850A1 (en) Substituted indoles, method for production and use thereof for the inhibition of pain
MXPA03006607A (es) Metodo combinado para tratar trastornos dependientes de hormonas.
MXPA03007653A (es) Uso de lp82 para tratar trastornos hematopoyeticos.
AU2002362115A8 (en) Composition and methods for treatment of neurological disorders
MXPA03004190A (es) Tratamiento de trastornos de ansiedad.
HK1077058A1 (en) Method of preparing derivatives of 1,5-diaryl-3-trifluoromethyl-delta2-pyrazolnes that are racemic and enantiomerically pure
AU2002228652A1 (en) Treatment of disorders using polyethylenimine diazeniumdiolate
GB0115581D0 (en) Method of mass spectometry
IL162053A0 (en) Method for the treatment of bone disorders
SI1468686T1 (sl) S-metil-dihidro-ziprazidon za zdravljenje psihiatricnih motenj
AU2001294377A1 (en) Method for the preparation of enantiomerically enriched amines
AU2002235448A1 (en) Process of enantiomerically enriched flavor and fragrance components
EP1425020A4 (en) METHOD AND COMPOSITIONS FOR TREATING APOPTOSIS-RELATED DISEASES
AUPQ872800A0 (en) Compositions and methods for treating cardiovascular disorders